# TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

> **NCT01354522** · PHASE3 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 204 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel, Doxorubicin, Cyclophosphamide
- **DRUG:** Docetaxel, Cyclophosphamide, Capecitabine

## Key facts

- **NCT ID:** NCT01354522
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01354522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01354522, "TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01354522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*